Opinion|Videos|August 28, 2024
Overview of the JUPITER and POLARIS-2 Trials
Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Have you had clinical experience with immune checkpoint inhibitors in combination with chemotherapy for your patients with NPC?
- Please give your thoughts on the JUPITER and POLARIS-2 trials in NPC.
Advertisement
Related to this article
The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
5